Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Current Deferred Revenue (2020 - 2025)

iSpecimen has reported Current Deferred Revenue over the past 6 years, most recently at $192535.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 46.62% year-over-year to $192535.0; the TTM value through Dec 2025 reached $192535.0, down 46.62%, while the annual FY2025 figure was $192535.0, 46.62% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $192535.0 at iSpecimen, up from $155506.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $802860.0 in Q2 2021 and troughed at $46910.0 in Q3 2023.
  • A 5-year average of $323280.5 and a median of $271444.5 in 2024 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 82.79% in 2023 and later skyrocketed 504.5% in 2024.
  • Year by year, Current Deferred Revenue stood at $654746.0 in 2021, then tumbled by 79.79% to $132335.0 in 2022, then skyrocketed by 214.18% to $415771.0 in 2023, then decreased by 13.24% to $360708.0 in 2024, then crashed by 46.62% to $192535.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for ISPC at $192535.0 in Q4 2025, $155506.0 in Q3 2025, and $164066.0 in Q2 2025.